EVOLENT HEALTH INC - A (EVH) Stock Fundamental Analysis
NYSE:EVH - New York Stock Exchange, Inc. - US30050B1017 - Common Stock - Currency: USD
EVH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 37 industry peers in the Health Care Technology industry. EVH has a bad profitability rating. Also its financial health evaluation is rather negative. EVH is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year EVH was profitable.
EVH had a positive operating cash flow in the past year.
In the past 5 years EVH always reported negative net income.
In multiple years EVH reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a decent Return On Assets value of -3.67%, EVH is doing good in the industry, outperforming 78.38% of the companies in the same industry.
EVH has a better Return On Equity (-7.84%) than 72.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.67% | ||
| ROE | -7.84% | ||
| ROIC | N/A |
ROA(3y)-3.35%
ROA(5y)-7.41%
ROE(3y)-7.16%
ROE(5y)-16.17%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EVH's Gross Margin of 14.38% is on the low side compared to the rest of the industry. EVH is outperformed by 78.38% of its industry peers.
EVH's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EVH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 14.38% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.51%
GM growth 5Y-10.71%
2. Health
2.1 Basic Checks
EVH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EVH has more shares outstanding
Compared to 5 years ago, EVH has more shares outstanding
Compared to 1 year ago, EVH has a worse debt to assets ratio.
2.2 Solvency
EVH has an Altman-Z score of 1.03. This is a bad value and indicates that EVH is not financially healthy and even has some risk of bankruptcy.
EVH's Altman-Z score of 1.03 is in line compared to the rest of the industry. EVH outperforms 56.76% of its industry peers.
A Debt/Equity ratio of 0.56 indicates that EVH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.56, EVH is not doing good in the industry: 62.16% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.03 |
ROIC/WACCN/A
WACC9.48%
2.3 Liquidity
A Current Ratio of 0.85 indicates that EVH may have some problems paying its short term obligations.
EVH has a Current ratio of 0.85. This is in the lower half of the industry: EVH underperforms 62.16% of its industry peers.
A Quick Ratio of 0.85 indicates that EVH may have some problems paying its short term obligations.
EVH has a Quick ratio of 0.85. This is in the lower half of the industry: EVH underperforms 62.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.85 | ||
| Quick Ratio | 0.85 |
3. Growth
3.1 Past
EVH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
The Earnings Per Share has been growing by 220.75% on average over the past years. This is a very strong growth
The Revenue has grown by 30.09% in the past year. This is a very strong growth!
The Revenue has been growing by 30.04% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-25%
EPS 3Y220.75%
EPS 5YN/A
EPS Q2Q%-108.7%
Revenue 1Y (TTM)30.09%
Revenue growth 3Y41.17%
Revenue growth 5Y30.04%
Sales Q2Q%16.27%
3.2 Future
The Earnings Per Share is expected to grow by 15.10% on average over the next years. This is quite good.
Based on estimates for the next years, EVH will show a quite strong growth in Revenue. The Revenue will grow by 8.69% on average per year.
EPS Next Y-28.27%
EPS Next 2Y2.36%
EPS Next 3Y15.02%
EPS Next 5Y15.1%
Revenue Next Year-19.11%
Revenue Next 2Y-3.12%
Revenue Next 3Y2.72%
Revenue Next 5Y8.69%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 15.08, EVH is valued correctly.
Based on the Price/Earnings ratio, EVH is valued cheaper than 89.19% of the companies in the same industry.
When comparing the Price/Earnings ratio of EVH to the average of the S&P500 Index (27.85), we can say EVH is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 21.02, the valuation of EVH can be described as rather expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EVH indicates a rather cheap valuation: EVH is cheaper than 86.49% of the companies listed in the same industry.
EVH is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 20.77, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.08 | ||
| Fwd PE | 21.02 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, EVH is valued cheaper than 89.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 13.26 |
4.3 Compensation for Growth
A more expensive valuation may be justified as EVH's earnings are expected to grow with 15.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.36%
EPS Next 3Y15.02%
5. Dividend
5.1 Amount
No dividends for EVH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
9.95
+0.09 (+0.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners110.19%
Inst Owner Change-0.69%
Ins Owners1.25%
Ins Owner Change4.63%
Market Cap1.16B
Analysts83.16
Price Target18.22 (83.12%)
Short Float %14.09%
Short Ratio5.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-210.68%
Min EPS beat(2)-332.96%
Max EPS beat(2)-88.41%
EPS beat(4)2
Avg EPS beat(4)-91.07%
Min EPS beat(4)-332.96%
Max EPS beat(4)39.63%
EPS beat(8)6
Avg EPS beat(8)5.92%
EPS beat(12)9
Avg EPS beat(12)545.39%
EPS beat(16)13
Avg EPS beat(16)470.93%
Revenue beat(2)0
Avg Revenue beat(2)-1.8%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)-1.7%
Revenue beat(4)2
Avg Revenue beat(4)0.62%
Min Revenue beat(4)-1.9%
Max Revenue beat(4)5.41%
Revenue beat(8)4
Avg Revenue beat(8)0.21%
Revenue beat(12)7
Avg Revenue beat(12)0.83%
Revenue beat(16)10
Avg Revenue beat(16)0.89%
PT rev (1m)-0.05%
PT rev (3m)-28.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-58.28%
EPS NY rev (1m)0%
EPS NY rev (3m)-52.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-35.3%
Revenue NY rev (1m)-1.88%
Revenue NY rev (3m)-24.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.08 | ||
| Fwd PE | 21.02 | ||
| P/S | 0.45 | ||
| P/FCF | N/A | ||
| P/OCF | 61.82 | ||
| P/B | 0.97 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.26 |
EPS(TTM)0.66
EY6.63%
EPS(NY)0.47
Fwd EY4.76%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)0.16
OCFY1.62%
SpS21.91
BVpS10.22
TBVpS-5.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.67% | ||
| ROE | -7.84% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 14.38% | ||
| FCFM | N/A |
ROA(3y)-3.35%
ROA(5y)-7.41%
ROE(3y)-7.16%
ROE(5y)-16.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.51%
GM growth 5Y-10.71%
F-Score6
Asset Turnover1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.72 | ||
| Cap/Depr | 21.03% | ||
| Cap/Sales | 0.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 16.21% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.85 | ||
| Quick Ratio | 0.85 | ||
| Altman-Z | 1.03 |
F-Score6
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)38.35%
Cap/Depr(5y)41.66%
Cap/Sales(3y)1.98%
Cap/Sales(5y)2.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y220.75%
EPS 5YN/A
EPS Q2Q%-108.7%
EPS Next Y-28.27%
EPS Next 2Y2.36%
EPS Next 3Y15.02%
EPS Next 5Y15.1%
Revenue 1Y (TTM)30.09%
Revenue growth 3Y41.17%
Revenue growth 5Y30.04%
Sales Q2Q%16.27%
Revenue Next Year-19.11%
Revenue Next 2Y-3.12%
Revenue Next 3Y2.72%
Revenue Next 5Y8.69%
EBIT growth 1Y-107.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year296.21%
EBIT Next 3Y81.54%
EBIT Next 5Y52.08%
FCF growth 1Y-105.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.84%
OCF growth 3Y-21.47%
OCF growth 5YN/A